LIVE

DYN

Dyne Therapeutics, Inc.

DYN

NASDAQ·Healthcare·Biotechnology·Mkt cap $3.6B

$22.95

▲ +5.30%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$8.06 - $25.00

P/E

-7.13

Fwd P/E

-7.06

Beta

1.08

Div Yield

0.00%

Avg Vol

1.8M

Shares Out

165.0M

Mkt Cap

$3.6B

Price action

Price chart

Up 143.7% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

3 reasons

  • Proprietary FORCE platform technology for targeted muscle disease therapeutic delivery
  • Focused pipeline addressing genetically driven muscle diseases with high unmet medical needs
  • Experienced management team with deep expertise in muscle biology and rare disease development
▼

Bear Case

1 risk

  • Average volatility.

Growth

Revenue decline expected

Clinical trial advancement and potential regulatory approvals for lead programs

Value

Deep value opportunity - significant discount to Biotech & Therapeutics peers

Momentum

Strong

+15.7% over 3m

Quality

Loss-making

Mixed fundamentals

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: Apr 30, 2026

“
Q2 26 RECAP

MAY 11, 2026

Reported EPS of -$0.73 vs -$0.77 consensus (+5.5% surprise).

EPS beat +5.5%

EPS surprise · last 4Q

1 of 1 beats

Q2 26

+5.5%

Next: Apr 30, 2026

Revenue trend · last 8Q

—

—

—

—

—

—

—

—

Q2 24

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

$0

$0

$0

$0

$0

$0

$0

$0

Margins · last 8Q

No margin history available.

View full earnings history →

Wall Street consensus

7 analysts · 71% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

5

71%

Hold

2

29%

Sell

0%

Median Price Target

$28.50

▲ +24.2% vs $22.95

Low $24.00
Median $28.50
High $33.00

Latest: TD Cowen · Jun 26, 2026

2 analysts covering

View full analyst page →

vs Industry

How DYN stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.